Maria Trypaki

1.1k total citations
26 papers, 869 citations indexed

About

Maria Trypaki is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Maria Trypaki has authored 26 papers receiving a total of 869 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 15 papers in Pulmonary and Respiratory Medicine and 12 papers in Cancer Research. Recurrent topics in Maria Trypaki's work include Lung Cancer Treatments and Mutations (12 papers), Cancer Genomics and Diagnostics (10 papers) and Colorectal Cancer Treatments and Studies (9 papers). Maria Trypaki is often cited by papers focused on Lung Cancer Treatments and Mutations (12 papers), Cancer Genomics and Diagnostics (10 papers) and Colorectal Cancer Treatments and Studies (9 papers). Maria Trypaki collaborates with scholars based in Greece, Cyprus and Sweden. Maria Trypaki's co-authors include John Souglakos, Vassilis Georgoulias, Anastasios Koutsopoulos, Efstathios N. Stathopoulos, Chara Papadaki, Alexandra Voutsina, Aristea Kalikaki, Dimitris Mavroudis, Maria Sfakianaki and D. Mavroudis and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Clinical Cancer Research.

In The Last Decade

Maria Trypaki

26 papers receiving 857 citations

Peers

Maria Trypaki
Satoshi Yoda Japan
Cristin Roma Italy
Raymond Wadlow United States
Jerry Haney United States
Michela Buscarino Italy
Shinnosuke Ikemura Japan
Alba Dalmases Spain
Karen Velastegui United States
Yuchen Bai United States
Timothy Larson United States
Satoshi Yoda Japan
Maria Trypaki
Citations per year, relative to Maria Trypaki Maria Trypaki (= 1×) peers Satoshi Yoda

Countries citing papers authored by Maria Trypaki

Since Specialization
Citations

This map shows the geographic impact of Maria Trypaki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maria Trypaki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maria Trypaki more than expected).

Fields of papers citing papers by Maria Trypaki

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maria Trypaki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maria Trypaki. The network helps show where Maria Trypaki may publish in the future.

Co-authorship network of co-authors of Maria Trypaki

This figure shows the co-authorship network connecting the top 25 collaborators of Maria Trypaki. A scholar is included among the top collaborators of Maria Trypaki based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maria Trypaki. Maria Trypaki is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lagoudaki, Eleni, Anastasios Koutsopoulos, Maria Sfakianaki, et al.. (2024). LKB1 Loss Correlates with STING Loss and, in Cooperation with β-Catenin Membranous Loss, Indicates Poor Prognosis in Patients with Operable Non-Small Cell Lung Cancer. Cancers. 16(10). 1818–1818. 2 indexed citations
2.
Messaritakis, Ippokratis, Maria Sfakianaki, Alexandra Voutsina, et al.. (2022). Prognostic Value of KRAS Mutations in Colorectal Cancer Patients. Cancers. 14(14). 3320–3320. 41 indexed citations
3.
Tsagkaris, Christos, Ippokratis Messaritakis, Nikolaos Gouvas, et al.. (2021). Resectable Colorectal Cancer: Current Perceptions on the Correlation of Recurrence Risk, Microbiota and Detection of Genetic Mutations in Liquid Biopsies. Cancers. 13(14). 3522–3522. 9 indexed citations
4.
Sfakianaki, Maria, Chara Papadaki, Maria Tzardi, et al.. (2020). PKM2 Expression as Biomarker for Resistance to Oxaliplatin-Based Chemotherapy in Colorectal Cancer. Cancers. 12(8). 2058–2058. 20 indexed citations
5.
Papadaki, Chara, Eleni Lagoudaki, Despo Ierodiakonou, et al.. (2020). Correlation of PKM2 and CD44 Protein Expression with Poor Prognosis in Platinum-Treated Epithelial Ovarian Cancer: A Retrospective Study. Cancers. 12(4). 1013–1013. 21 indexed citations
6.
Ioannidis, Georgios, Chara Papadaki, Eleni Lagoudaki, et al.. (2020). Messenger-RNA Expression of Five Gemcitabine Sensitivity-related Genes Predicting Outcome in Advanced-stage Non-small Cell Lung Cancer. Anticancer Research. 40(2). 901–913. 1 indexed citations
7.
Sfakianaki, Maria, Chara Papadaki, Maria Tzardi, et al.. (2019). PKM2 expression as biomarker for resistance to oxaliplatin-based chemotherapy in colorectal cancer. Annals of Oncology. 30. iv21–iv22. 9 indexed citations
8.
Sfakianaki, Maria, Chara Papadaki, Maria Tzardi, et al.. (2019). Loss of LKB1 Protein Expression Correlates with Increased Risk of Recurrence and Death in Patients with Resected, Stage II or III Colon Cancer. Cancer Research and Treatment. 51(4). 1518–1526. 12 indexed citations
9.
10.
Matikas, Alexios, Alexandra Voutsina, Eleni Lagoudaki, et al.. (2017). Detection of KRAS Exon 2 Mutations in Circulating Tumor Cells Isolated by the ISET System from Patients with RAS Wild Type Metastatic Colorectal Cancer. Translational Oncology. 10(4). 693–698. 7 indexed citations
11.
Matikas, Alexios, Alexandra Voutsina, Maria Trypaki, & Vassilis Georgoulias. (2016). Role of circulating free DNA in colorectal cancer. World Journal of Gastrointestinal Oncology. 8(12). 810–810. 6 indexed citations
12.
Papadaki, Chara, Maria Sfakianaki, Eleni Lagoudaki, et al.. (2014). PKM2 as a biomarker for chemosensitivity to front-line platinum-based chemotherapy in patients with metastatic non-small-cell lung cancer. British Journal of Cancer. 111(9). 1757–1764. 51 indexed citations
13.
14.
Papadaki, Chara, Maria Sfakianaki, Georgios Ioannidis, et al.. (2012). ERCC1 and BRAC1 mRNA Expression Levels in the Primary Tumor Could Predict the Effectiveness of the Second-Line Cisplatin-Based Chemotherapy in Pretreated Patients with Metastatic Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 7(4). 663–671. 44 indexed citations
15.
Saridaki, Zacharenia, Maria Tzardi, Chara Papadaki, et al.. (2011). Impact of KRAS, BRAF, PIK3CA Mutations, PTEN, AREG, EREG Expression and Skin Rash in ≥2nd Line Cetuximab-Based Therapy of Colorectal Cancer Patients. PLoS ONE. 6(1). e15980–e15980. 101 indexed citations
16.
Papadaki, Chara, Zacharenia Saridaki, Maria Sfakianaki, et al.. (2011). PKM2 as a biomarker for sensitivity to oxaliplatin-based chemotherapy in metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology. 29(4_suppl). 434–434. 2 indexed citations
17.
Papadaki, Chara, L Kaklamanis, Eleni Lagoudaki, et al.. (2010). Correlation of BRCA1, TXR1 and TSP1 mRNA expression with treatment outcome to docetaxel-based first-line chemotherapy in patients with advanced/metastatic non-small-cell lung cancer. British Journal of Cancer. 104(2). 316–323. 27 indexed citations
18.
Kalikaki, Aristea, Anastasios Koutsopoulos, Dora Hatzidaki, et al.. (2009). Clinical outcome of patients with non-small cell lung cancer receiving front-line chemotherapy according to EGFR and K-RAS mutation status. Lung Cancer. 69(1). 110–115. 76 indexed citations
19.
Kalikaki, Aristea, Anastasios Koutsopoulos, Maria Trypaki, et al.. (2008). Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC. British Journal of Cancer. 99(6). 923–929. 182 indexed citations
20.
Voutsina, Alexandra, Anastasios Koutsopoulos, Athanasios Pallis, et al.. (2007). P3-157: Correlation of EGFR mutation status between primary tumor and metastases in NSCLC. Journal of Thoracic Oncology. 2(8). S746–S746. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Satoshi Yoda Breakdown of academic impact, for papers by Cristin Roma Breakdown of academic impact, for papers by Raymond Wadlow Breakdown of academic impact, for papers by Jerry Haney Breakdown of academic impact, for papers by Michela Buscarino Breakdown of academic impact, for papers by Shinnosuke Ikemura Breakdown of academic impact, for papers by Alba Dalmases Breakdown of academic impact, for papers by Karen Velastegui Breakdown of academic impact, for papers by Yuchen Bai Breakdown of academic impact, for papers by Timothy Larson
Rankless by CCL
2026